Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - stiripentol, quantity: 250 mg - capsule - excipient ingredients: sodium starch glycollate type a; magnesium stearate; povidone; gelatin; titanium dioxide; erythrosine; indigo carmine; shellac; iron oxide black - diacomit is indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - stiripentol, quantity: 250 mg - powder, oral - excipient ingredients: sodium starch glycollate type a; povidone; spray-dried liquid glucose; erythrosine; titanium dioxide; aspartame; carmellose; hyetellose; flavour - diacomit is indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - stiripentol, quantity: 500 mg - powder, oral - excipient ingredients: sodium starch glycollate type a; povidone; spray-dried liquid glucose; erythrosine; titanium dioxide; aspartame; carmellose; hyetellose; flavour - diacomit is indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - stiripentol, quantity: 500 mg - capsule - excipient ingredients: sodium starch glycollate type a; magnesium stearate; povidone; gelatin; titanium dioxide; iron oxide black; shellac - diacomit is indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.

European Union - English - EMA (European Medicines Agency)

biocodex - stiripentol - myoclonic epilepsy, juvenile - antiepileptics, - diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (smei, dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.

Canada - English - Health Canada

biocodex sas - stiripentol - capsule - 250mg - stiripentol 250mg - miscellaneous anticonvulsants

Canada - English - Health Canada

biocodex sas - stiripentol - capsule - 500mg - stiripentol 500mg - miscellaneous anticonvulsants

Canada - English - Health Canada

biocodex sas - stiripentol - powder for suspension - 250mg - stiripentol 250mg - miscellaneous anticonvulsants

Canada - English - Health Canada

biocodex sas - stiripentol - powder for suspension - 500mg - stiripentol 500mg - miscellaneous anticonvulsants

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - primidone, quantity: 250 mg - tablet, uncoated - excipient ingredients: carmellose calcium; povidone; gelatin; magnesium stearate; stearic acid - management of grand mal and psychomotor (temporal lobe) epilepsy. it is also of value in the management of focal or jacksonian seizures, myoclonic jerks and akinetic attacks.